Overestimation of the effects of adherence on outcomes: A case study in healthy user bias and hypertension

Heart

Volumn 97, Issue 22, 2011, Pages 1862-1869

  LaFleur, Joanne ^a,b   Nelson, Richard E ^b,c   Sauer, Brian C ^b,c   Nebeker, Jonathan R ^b  

^a UNIVERSITY OF UTAH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CONFOUNDING VARIABLE; DEATH; HEALTHY USER BIAS; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; SYSTEMATIC ERROR; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BIAS (EPIDEMIOLOGY); BLOOD PRESSURE; CASE-CONTROL STUDIES; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INPATIENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK ASSESSMENT; RISK FACTORS; SAMPLING STUDIES; TREATMENT OUTCOME; UNITED STATES; VETERANS;

EID: 80055102131     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.223289     Document Type: Article

References (49)

1. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9. (Pubitemid 351222546)
2. Hood KK, Peterson CM, Rohan JM, et al. Association between adherence and glycemic control in pediatric type 1 diabetes: a meta-analysis. Pediatrics 2009;124:e1171-9.
3. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605.
4. Nachega JB, Leisegang R, Bishai D, et al. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med 2010;152:18-25.
5. Perreault S, Dragomir A, White M, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009;266:207-18.
6. Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med 2009;122:647-55.
7. Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009;9:2597-606.
8. Salas M, Hughes D, Zuluaga A, et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009;12:915-22.
9. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009;169:260-8.
10. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122:S3-13.
11. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. (Pubitemid 40617065)
12. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9. (Pubitemid 44305292)
13. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68. (Pubitemid 46089732)
14. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-18. (Pubitemid 46294748)
15. Stroupe KT, Teal EY, Tu W, et al. Association of refill adherence and health care use among adults with hypertension in an urban health care system. Pharmacotherapy 2006;26:779-89. (Pubitemid 43807629)
16. Sun SX, Ye X, Lee KY, et al. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction. Clin Ther 2008;(30 Pt 2):2217-27.
17. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41. (Pubitemid 44455165)
18. Wu PH, Yang CY, Yao ZL, et al. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens 2010;23:155-60.
19. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008;24:121-7. (Pubitemid 351160245)
20. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9. (Pubitemid 351410514)
21. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009;(3):CD001841.
22. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54. (Pubitemid 47216808)
23. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
24. Ray WA, Daugherty JR, Griffin MR. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 2002;8:276-9.
25. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999.
26. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006;333:15.
27. National Heart Lung and Blood Institute. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC7). 2003. http://www.nhlbi.nih.gov/guidelines/hypertension/ (accessed 15 Dec 2008).
28. LaFleur J, Nelson RE, Sauer BS, et al. Any-cause hospitalization outcomes associated with poor patient adherence to antihypertensives. 2nd International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia, and Diabetes Mellitus. Valencia, Spain,10-12 December 2009.
29. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16. (Pubitemid 27089212)
30. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12. (Pubitemid 46161090)
31. Blanc PD, Yen IH, Chen H, et al. Area-level socio-economic status and health status among adults with asthma and rhinitis. Eur Respir J 2006;27:85-94. (Pubitemid 43092671)
32. Peduzzi P, Wittes J, Detre K, et al. Analysis as-randomized and the problem of nonadherence: an example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery. Stat Med 1993;12:1185-95. (Pubitemid 23220539)
33. Greene T, Daugirdas J, Depner T, et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". J Am Soc Nephrol 2005;16:3371-80. (Pubitemid 46187551)
34. Peduzzi P, Detre K, Wittes J, et al. Intent-to-treat analysis and the problem of crossovers. An example from the Veterans Administration coronary bypass surgery study. J Thorac Cardiovasc Surg 1991;101:481-7.
35. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
36. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53.
37. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000;21:193-221. (Pubitemid 30480322)
38. Imbens GW, Rubin DB. Bayesian inference for causal effects in randomized experiments with noncompliance. Ann Stat 1997;25:305-27.
39. Joffe MM, Brensinger C. Weighting in instrumental variables and G-estimation. Stat Med 2003;22:1285-303. (Pubitemid 36526954)
40. Goetghebeur E, Stijn V. Structural mean models for compliance analysis in randomized clinical trials and the impact of errors on measures of exposure. Stat Methods Med Res 2005;14:397-415. (Pubitemid 41300813)
41. Vittinghoff E, Glidden D, Shiboski S, et al. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models. New York: Springer, 2005:95-8.
42. Curry RC Jr, Schwartz KM, Urban PL. Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison. S Med J 1988;81:1401-6, 11.
43. Gavras HP, Salerno CM. The angiotensin II type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996;18:1058-67. (Pubitemid 27077110)
44. Giles TD, Robinson TD. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. Am J Hypertens 2004;17:690-5. (Pubitemid 39099176)
45. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007;9:760-9.
46. Heran BS, Wong MM, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008;(4):CD003822.
47. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62. (Pubitemid 23335891)
48. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81. (Pubitemid 23102690)
49. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7. (Pubitemid 29290470)